{
    "ticker": "PIRS",
    "name": "Pieris Pharmaceuticals, Inc.",
    "description": "Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of cancer and other serious diseases. Founded in 2008 and headquartered in Boston, Massachusetts, Pieris is pioneering the use of its proprietary Anticalin\u00ae technology to develop a new class of medicines known as targeted therapeutics. These are designed to specifically bind to disease targets, improving efficacy and reducing side effects compared to traditional therapies. The company is advancing a robust pipeline of drug candidates, including their lead program, PRS-343, which is being developed for the treatment of cancer. Pieris employs a strategic approach that combines its proprietary technology with collaborations with leading pharmaceutical companies to enhance drug development and commercialization efforts. Their mission is to transform the treatment landscape for patients suffering from serious diseases by delivering innovative and effective therapies that can improve patient outcomes and quality of life.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Boston, Massachusetts, USA",
    "founded": "2008",
    "website": "https://www.pieris.com",
    "ceo": "Stephen Yoder",
    "social_media": {
        "twitter": "https://twitter.com/PierisPharma",
        "linkedin": "https://www.linkedin.com/company/pieris-pharmaceuticals"
    },
    "investor_relations": "https://investors.pieris.com",
    "key_executives": [
        {
            "name": "Stephen Yoder",
            "position": "CEO"
        },
        {
            "name": "Ellen O'Dowd",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology",
            "products": [
                "PRS-343"
            ]
        }
    ],
    "seo": {
        "meta_title": "Pieris Pharmaceuticals, Inc. | Innovative Biopharmaceutical Solutions",
        "meta_description": "Explore Pieris Pharmaceuticals, Inc., a leader in the development of Anticalin-based therapeutics for cancer and serious diseases. Learn more about our innovative approach and pipeline.",
        "keywords": [
            "Pieris Pharmaceuticals",
            "Biopharmaceuticals",
            "Anticalin",
            "Cancer Treatment",
            "Innovative Therapies"
        ]
    },
    "faq": [
        {
            "question": "What is Pieris Pharmaceuticals known for?",
            "answer": "Pieris Pharmaceuticals is known for its innovative Anticalin technology and its development of targeted therapeutics for cancer and other serious diseases."
        },
        {
            "question": "Who is the CEO of Pieris Pharmaceuticals?",
            "answer": "Stephen Yoder is the CEO of Pieris Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Pieris Pharmaceuticals headquartered?",
            "answer": "Pieris Pharmaceuticals is headquartered in Boston, Massachusetts, USA."
        },
        {
            "question": "What are Pieris Pharmaceuticals' main products?",
            "answer": "Pieris Pharmaceuticals' main product in development is PRS-343, targeting cancer."
        },
        {
            "question": "When was Pieris Pharmaceuticals founded?",
            "answer": "Pieris Pharmaceuticals was founded in 2008."
        }
    ],
    "competitors": [
        "AMGN",
        "BMY",
        "REGN",
        "INCY"
    ],
    "related_stocks": [
        "AAPL",
        "MSFT",
        "GILD",
        "JNJ"
    ]
}